CJC-1295 With DAC (Drug Affinity Complex) is a synthetic 30-amino acid analogue of growth hormone-releasing hormone (GHRH). With a molecular weight of 3647.28 g/mol, CJC-1295 DAC (CAS 446262-90-4) features a maleimidopropionyl group conjugated to a C-terminal lysine residue, designed to facilitate bioconjugation with serum albumin. Produced via solid-phase peptide synthesis, CJC-1295 DAC acts at the GHRH receptor (GHRH-R).

CJC-1295 With DAC is investigated in preclinical endocrinology for its extended pharmacokinetic profile relative to unmodified GHRH analogues. The DAC bioconjugation strategy represents a distinct approach to prolonging peptide half-life through albumin binding rather than sequence modification alone, and has been a subject of particular research interest. In vitro studies in rat anterior pituitary somatotroph preparations have examined GHRH-R binding characteristics and downstream cAMP-mediated signalling, characterising the receptor binding kinetics that underpin CJC-1295 DAC’s agonist activity at GHRH-R [1]. Published pharmacokinetic studies in rodent models have investigated sustained receptor engagement and prolonged circulating peptide concentrations following a single administration, with researchers examining albumin-peptide dissociation kinetics and their implications for extended receptor occupancy duration [2].

CJC-1295 With DAC is manufactured in a cGMP compliant laboratory to a guaranteed purity of 98% or above. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

Editorial Team

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed and approved 14 June 2026

View credentials →